PharmaCyte Financial Statements From 2010 to 2025

PMCB Stock  USD 1.58  0.09  5.39%   
PharmaCyte Biotech financial statements provide useful quarterly and yearly information to potential PharmaCyte Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on PharmaCyte Biotech financial statements helps investors assess PharmaCyte Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting PharmaCyte Biotech's valuation are summarized below:
Market Capitalization
11 M
Earnings Share
0.88
We have found one hundred twenty available trending fundamental ratios for PharmaCyte Biotech, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of PharmaCyte Biotech recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 29.6 M, whereas Enterprise Value is projected to grow to (25.5 M).

PharmaCyte Biotech Total Revenue

0.0

Check PharmaCyte Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PharmaCyte Biotech's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Other Operating Expenses of 5.6 M or EBITDA of 315.4 K, as well as many indicators such as Price To Sales Ratio of 3.3 K, Dividend Yield of 0.0014 or PTB Ratio of 0.49. PharmaCyte financial statements analysis is a perfect complement when working with PharmaCyte Biotech Valuation or Volatility modules.
  
Check out the analysis of PharmaCyte Biotech Correlation against competitors.
For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.

PharmaCyte Biotech Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities8.1 M7.7 M1.9 M
Slightly volatile
Total Current LiabilitiesM8.5 M2.5 M
Slightly volatile
Common Stock Total Equity17418350 K
Slightly volatile
Common Stock Shares Outstanding10.5 M11 M323.2 M
Pretty Stable
Total Liabilities24.6 M23.4 M5.3 M
Slightly volatile
Common Stock2.4 K2.5 K50.7 K
Slightly volatile
Total Assets72.3 M68.9 M26.8 M
Slightly volatile
Short and Long Term Debt Total43.4 K45.7 K223.8 K
Slightly volatile
Other Liabilities4.4 K4.6 K4.1 K
Slightly volatile
Property Plant And Equipment Net117.5 K123.7 K105.3 K
Slightly volatile
Accounts Payable322.7 K447.8 K299.7 K
Very volatile
Cash60.6 M57.7 M21.2 M
Slightly volatile
Non Current Assets Total11.4 M10.9 M5.3 M
Slightly volatile
Non Currrent Assets Other9.6 M9.1 M1.8 M
Slightly volatile
Long Term Debt39.6 K41.7 K63 K
Slightly volatile
Cash And Short Term Investments60.6 M57.7 M21.3 M
Slightly volatile
Liabilities And Stockholders Equity72.3 M68.9 M26.8 M
Slightly volatile
Inventory5.9 K6.2 K9.3 K
Slightly volatile
Total Current Assets60.9 M58 M21.5 M
Slightly volatile
Property Plant Equipment59 K62.1 K54.3 K
Slightly volatile
Net Receivables2.2 K2.3 K2.4 K
Slightly volatile
Short Term Investments1.9 M1.8 M1.5 M
Slightly volatile
Intangible Assets3.1 M1.8 M3.1 M
Very volatile
Good Will1.7 M1.9 M2.1 M
Slightly volatile
Short Term Debt43.4 K45.7 K216.5 K
Slightly volatile
Preferred Stock Total Equity616 K667 K582.7 K
Slightly volatile
Net Tangible Assets104.3 M99.3 M31.5 M
Slightly volatile
Short and Long Term Debt24.7 K26 K57.2 K
Slightly volatile
Net Invested Capital30.4 M31.8 M20.7 M
Slightly volatile
Capital Stock14.3 M13.6 M2.6 M
Slightly volatile

PharmaCyte Biotech Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses5.6 M7.5 MM
Very volatile
Total Operating Expenses5.7 M9.8 M6.3 M
Very volatile
Selling General Administrative4.8 M5.5 MM
Very volatile
Research Development923.4 K468.5 K881.9 K
Pretty Stable
Selling And Marketing Expenses1.6 M1.5 M1.1 M
Slightly volatile
Non Recurring485.7 K430.8 K601.6 K
Slightly volatile

PharmaCyte Biotech Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow60.6 M57.7 M21.2 M
Slightly volatile
Dividends Paid27.1 M25.8 M21.6 M
Slightly volatile
Stock Based Compensation577607838.5 K
Pretty Stable
Change To Netincome96.4 K101.5 K7.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.3 K3.2 K3.2 K
Slightly volatile
Dividend Yield0.00140.00160.0017
Slightly volatile
Days Sales Outstanding15.4616.2813.9593
Slightly volatile
Average Payables210.3 K161.1 K262.7 K
Slightly volatile
Stock Based Compensation To Revenue0.06480.07290.0795
Slightly volatile
Capex To Depreciation0.150.160.1744
Slightly volatile
EV To Sales3.4 K3.2 K3.2 K
Slightly volatile
Inventory Turnover2.422.552.6121
Slightly volatile
Days Of Inventory On Hand1411481.5 K
Slightly volatile
Payables Turnover0.02990.03140.036
Slightly volatile
Sales General And Administrative To Revenue123117115
Slightly volatile
Average Inventory51.1 K53.8 K56.6 K
Pretty Stable
Research And Ddevelopement To Revenue0.07980.084137.011
Slightly volatile
Capex To Revenue0.00850.00891.1876
Slightly volatile
Cash Per Share4.696.023.5553
Pretty Stable
Days Payables Outstanding12.6 K12 K12.4 K
Slightly volatile
Intangibles To Total Assets0.02830.02970.3178
Slightly volatile
Current Ratio7.437.8249.4996
Slightly volatile
Receivables Turnover18.7323.2126.5728
Slightly volatile
Graham Number1.441.621.7644
Slightly volatile
Capex Per Share8.58.18.3925
Slightly volatile
Average Receivables1.4 K1.5 K8.5 K
Slightly volatile
Revenue Per Share0.04520.04750.0558
Slightly volatile
Interest Debt Per Share0.00.01.0506
Slightly volatile
Debt To Assets0.00750.00790.1946
Slightly volatile
Operating Cycle1561651.5 K
Slightly volatile
Days Of Payables Outstanding12.6 K12 K12.4 K
Slightly volatile
Long Term Debt To Capitalization0.00850.00810.1268
Slightly volatile
Quick Ratio7.437.8238.1757
Pretty Stable
Net Income Per E B T1.131.111.0194
Very volatile
Cash Ratio7.397.7837.9383
Pretty Stable
Days Of Inventory Outstanding1411481.5 K
Slightly volatile
Days Of Sales Outstanding15.4616.2813.9593
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio3.062.923.0689
Slightly volatile
Fixed Asset Turnover2.532.662.2082
Slightly volatile
Debt Ratio0.00750.00790.1946
Slightly volatile
Price Sales Ratio3.3 K3.2 K3.2 K
Slightly volatile
Asset Turnover0.00460.00490.0066
Slightly volatile
Gross Profit Margin0.230.240.2724
Slightly volatile

PharmaCyte Biotech Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap29.6 M18.3 M50.3 M
Pretty Stable

PharmaCyte Fundamental Market Drivers

Cash And Short Term Investments50.2 M

PharmaCyte Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
31st of January 2024
Next Fiscal Quarter End
View

About PharmaCyte Biotech Financial Statements

PharmaCyte Biotech stakeholders use historical fundamental indicators, such as PharmaCyte Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although PharmaCyte Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in PharmaCyte Biotech's assets and liabilities are reflected in the revenues and expenses on PharmaCyte Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in PharmaCyte Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-45.7 K-43.4 K
Stock Based Compensation To Revenue 0.07  0.06 
Sales General And Administrative To Revenue 116.98  122.83 
Research And Ddevelopement To Revenue 0.08  0.08 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.05  0.05 
Ebit Per Revenue(124.66)(130.90)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether PharmaCyte Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PharmaCyte Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacyte Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacyte Biotech Stock:
Check out the analysis of PharmaCyte Biotech Correlation against competitors.
For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.88
Return On Assets
(0.05)
Return On Equity
0.4318
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.